Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 111759000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 18.69% year-over-year to 111759000.0; the TTM figure through Mar 2026 stood at 357786000.0 (down 5.95% YoY), while the FY2025 annual figure was 652819000.0, down 37.16% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 111759000.0, down from 99309000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 25693000.0 in Q1 2022, with the low at 111759000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 68186000.0 (2023), against an average of 66943941.18.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations tumbled 165.39% in 2023, then surged 61.69% in 2025.
• Viridian Therapeutics, Inc.\DE's Income from Continuing Operations stood at 45610000.0 in 2022, then slumped by 84.56% to 84179000.0 in 2023, then advanced by 6.04% to 79092000.0 in 2024, then declined by 25.56% to 99309000.0 in 2025, then dropped by 12.54% to 111759000.0 in 2026.
• Business Quant data shows VRDN's Income from Continuing Operations at 111759000.0 in Q1 2026, 99309000.0 in Q4 2025, and 35052000.0 in Q3 2025.